Antibody-mediated Rejection: Clinical Trials

7 trials for Antibody-mediated Rejection, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 terminated, 2 active not recruiting, 1 completed, 1 enrolling by invitation. 7 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 37Terminated 3, Active not recruiting 2, Completed 1, Enrolling by invitation 1

Follow Antibody-mediated Rejection: new trials by email Literature Review of Antibody-mediated Rejection trials Research Report on Antibody-mediated Rejection

Trials (filtered) newest first · largest first

All 7 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study to Learn More About the Long-Term Safety and Effects of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR) or Microvascular Inflammation (MVI) (TRANSCEND/TRANSPIRE LTE)
Felzartamab - Antibody-mediated Rejection, Microvascular Inflammation
Phase 3Enrolling by invitationBiogen2012026-04-162026-11-02
A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR)
Felzartamab, Placebo - Antibody-mediated Rejection
Phase 3Active not recruitingBiogen1322024-12-032026-06-05
TocIlizumab in Late/Chronic Active Antibody-mediated Rejection in Kidney Transplant Recipients
Tocilizumab - Antibody-mediated Rejection
Phase 3Active not recruitingVastra Gotaland Region502022-02-012026-08-10
Clazakizumab for the Treatment of Chronic Active Antibody Mediated Rejection in Kidney Transplant Recipients
Clazakizumab, Physiologic saline solution - Antibody-mediated Rejection
Phase 3TerminatedCSL Behring1942019-10-142025-07-23
Transplant Antibody-Mediated Rejection: Guiding Effective Treatments
Rituximab, Methylprednisolone, Intravenous Immunoglobulin - Kidney Transplant Rejection, Antibody-mediated Rejection
Phase 3TerminatedImperial College London32019-07-172025-04-13
Efficacy and Safety of Human Plasma-derived C1-esterase Inhibitor as add-on to Standard of Care for the Treatment of Refractory Antibody Mediated Rejection (AMR) in Adult Renal Transplant Recipients
C1-esterase inhibitor, Placebo - Antibody-mediated Rejection
Phase 3TerminatedCSL Behring632017-11-062022-07-29
The De-novo Use of Eculizumab in Presensitized Patients Receiving Cardiac Transplantation
Eculizumab - Antibody-mediated Rejection, Hyperacute Rejection of Cardiac Transplant
Phase 3CompletedCedars-Sinai Medical Center362012-11-012021-05-03

Narrower conditions

Complement Component 3 Deficiency, Autosomal Recessive (1)  ·  Ventricular Dysfunction, Left (1)

Broader conditions

Cardiovascular Diseases (1)  ·  Heart Diseases (1)  ·  Ventricular Dysfunction (1)

Interventions

felzartamab (2)  ·  Complement C1 Inhibitor Protein (1)  ·  Immunoglobulins, Intravenous (1)  ·  Methylprednisolone (1)  ·  Plasma Exchange (1)  ·  Rituximab (1)  ·  clazakizumab (1)  ·  eculizumab (1)  ·  tocilizumab (1)

Sponsors

Biogen (2)  ·  CSL Behring (2)  ·  Cedars-Sinai Medical Center (1)  ·  Imperial College London (1)  ·  Vastra Gotaland Region (1)

Countries

United States (5)  ·  Spain (4)  ·  Canada (3)  ·  France (3)  ·  Germany (3)  ·  Australia (2)  ·  Austria (2)  ·  Belgium (2)  ·  Czechia (2)  ·  Netherlands (2)  ·  New Zealand (2)  ·  Sweden (2)  ·  United Kingdom (2)  ·  Argentina (1)  ·  Brazil (1)

Top investigators

Jignesh Patel, M.D., Ph.D. (1)  ·  Michelle Willicombe, MA MRCP MD (1)  ·  Seema Baid-Agrawal, MD, FASN (1)

Results publications

PMID 40444214, PMID 33251691, PMID 33332922, PMID 35497778, PMID 35969004, PMID 36550562, PMID 37182818, PMID 38519988, PMID 39102302, PMID 41430762

NIH funding

2018 (2), 2017 (1), 2019 (1)